Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+/-)Nicotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 0.97 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.97 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.97 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.97 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.97 |
| ▸ | HTR3B | O95264 | 1/20 | 0.97 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.97 |
| ▸ | CHRNG | P07510 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.97 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicotine SCHEMBL4615064 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL29352733 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL15561442 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL27784105 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL15561440 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL676683 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL30339296 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL9383177 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL9383182 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL28285656 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4070671-B1 | A FLAVOURED ORAL POUCHED NICOTINE PRODUCT COMPRISING AN ACID | SWEDISH MATCH NORTH EUROPE AB (SE) | 2024-03-27 | — | — | EP | claimed |
| EP-3393565-B1 | NICOTINE PARTICLE CAPSULE | PHILIP MORRIS PRODUCTS SA (CH) | 2023-05-24 | — | — | EP | claimed |
| CN-113273731-A | Nicotine powder delivery system | 菲利普莫里斯生产公司 | 2021-08-20 | — | — | CN | claimed |
| CN-108463262-B | Nicotine powder delivery system | 菲利普莫里斯生产公司 | 2021-06-11 | — | — | CN | claimed |
| EP-3481472-B1 | NICOTINE PARTICLE DELIVERY CONSUMABLE | PHILIP MORRIS PRODUCTS SA (CH) | 2020-08-05 | — | — | EP | claimed |
| CN-111447921-A | Nicotine tablet | 费尔廷制药公司 | 2020-07-24 | — | — | CN | claimed |
| EP-2830622-B1 | A NICOTINE ORAL DELIVERY PRODUCT CONTAINING A POWDER ENCLOSED IN A WATER INSOLUBLE POUCH, WHEREIN SAID POWDER COMPRISES NICOTINE AND A CHEWING GUM COMPOSITION | FNYZ AB (SE) | 2018-08-01 | — | — | EP | claimed |
| CN-107613762-A | Methods and compositions for reducing tobacco-specific nitrosamine NNK in tobacco | 北卡罗莱纳州立大学 | 2018-01-19 | — | — | CN | claimed |
| EP-1458252-B1 | TOBACCO AND/OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | GALENICA AB (SE) | 2008-01-23 | — | — | EP | claimed |
| CN-1838878-A | Reduced-exposure tobacco products | 22ND CENTURY LTD LLC (US) | 2006-09-27 | — | — | CN | claimed |
| US-12595237-B2 | Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| CN-114568018-B | Inhaler article with tangential airflow end elements | 菲利普莫里斯生产公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119173163-A | Article for a dry powder inhaler having indicia on the upstream end | 菲利普莫里斯生产公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119136701-A | Method of manufacturing an article for a dry powder inhaler with an upstream elastic element | 菲利普莫里斯生产公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-113273731-B | Nicotine powder delivery system | 菲利普莫里斯生产公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-101296691-A | transdermal drug delivery dosage form | NUVO RES INC (CA) | 2008-10-29 | — | — | CN | disclosed |
| CN-1838878-A | Reduced-exposure tobacco products | 22ND CENTURY LTD LLC (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-0871613-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-21 | — | — | EP | disclosed |
| US-5753679-A | SCIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1996035666-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595237-B2 | Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same | CACNA1S, CACNA1D, CACNA1F | CHRNB2 1170/4885CHRNA4 422/4885ALDH1A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.